INNATE PHARMA: Report and termination of the liquidity contract with Gilbert Dupont
Marseille, France, May 18, 2016
The company Innate Pharma and the brokerage firm Gilbert Dupont have ended the liquidity contract signed on July 27, 2012. The termination is effective from May 13, 2016 after market.
As at May 13, 2016 after market, the following assets appeared on the liquidity account:
- 18,575 shares of Innate Pharma that will be kept in shares portfolio, and
- 372,807.10 euros in cash.
As a reminder, at December 31, 2015, the following assets appeared on the liquidity account:
- 22,128 shares of Innate Pharma, and
- 358,336.72 euros in cash.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.
The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com .
Practical Information about Innate Pharma shares:
|
ISIN code
Ticker code |
FR0010331421
IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( http://www.amf-france.org ) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
| Innate Pharma | Press Contacts |
|
Laure-Hélène Mercier
Director, Investor Relations |
ATCG
Marie Puvieux |
| Tel.: +33 (0)4 30 30 30 87 | Mob: +33 (0)6 10 54 36 72 |
| investors@innate-pharma.com | presse@atcg-partners.com |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INNATE PHARMA via GlobeNewswire
